Clinical trial

Transfusion of Red Blood Cells (RBC), Tranexamic Acid (TXA) and Fibrinogen Concentrate (FC) for Severe Trauma Hemorrhage at Pre-hospital Phase of Care. A Pilot Trial.

Name
PRETIC
Description
This is a single-center, not-randomized, open-label, controlled pilot clinical trial. This study compares presence of Trauma Induced Coagulopathy (TIC) and acute traumatic hemorrhage treatment at pre-hospital phase of care with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC) with the current treatment based on the administration of Crystalloids and TXA.
Trial arms
Trial start
2018-11-21
Estimated PCD
2021-01-11
Trial end
2022-01-11
Status
Completed
Phase
Early phase I
Treatment
Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
Administration of 2 mg of FC together with RBC and TXA
Arms:
Experimental treatment
Red blood cells concentrate
Administration of 2 red blood cells concentrates together with FC and TXA
Arms:
Experimental treatment
Tranexamic Acid
Administration of 1g of TXA together with FC and RBC
Arms:
Experimental treatment, Standard treatment
Size
79
Primary endpoint
TEG6s(R) parameters for Trauma Induced Coagulopathy (TIC)
Basal (at the crash site)
TEG6s(R) parameters for Trauma Induced Coagulopathy (TIC)
Basal (at the hospital arrival)
All-cause mortality
1 hour post hospital admission
All-cause mortality
6 hours post hospital admission
All-cause mortality
24 hours post hospital admission
Accountability
30 days
Temperature storage conditions of the red blood cells concentrate
24 hours
Eligibility criteria
Inclusion Criteria: * Age ≥18 years AND * Patients with severe trauma categorized as priority 0 or 1 according to the CatSalut Polytrauma Code (PPT) AND * Evidence of bleeding or a high bleeding suspicion according to physician judgment OR * Predicted to need transfusion according to TICCS score ≥10 Exclusion Criteria: * Moribund patient with devastating injuries and expected to die within 1-hour OR * Known objection to blood components transfusion OR * Known acquired or congenital coagulopathies not related to the actual trauma OR * Known anticoagulant treatment (vitamin K antagonist, dabigatran, rivaroxaban, apixaban) OR * Known Pregnancy OR * Severe isolated traumatic brain injury OR * Hemorrhage not related to the actual trauma
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Single-center, non-randomized, open-label, two-arms, controlled pilot clinical trial.\n\nThe experimental and control arms will be determined according to the SEM units with RBC, TXA and FC administration capacity (i.e. helicopter unit, rapid intervention ambulance or advanced life support ambulance). The emergency SEM units are activated according current protocols based on distance, severity and weather conditions.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 79, 'type': 'ACTUAL'}}
Updated at
2024-01-25

1 organization

3 products

2 indications

Indication
Polytrauma